The offshoot starts life with seed funding and an RNA-based program targeting a rare genetic disease that causes strokes.
The red-blood-cell-encapsulated L-asparaginase improved overall survival and other outcomes in metastatic pancreatic cancer patients.
The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.
After getting off a $102 million series A, Gritstone Oncology has followed up with an impressive $92.7 million second round.
Wednesday's shot of your news of note.
Stemcentrx backer Artis Ventures led the $10 million seed round to equip Excision to start human testing of its CRISPR-enabled attack on latent HIV.
The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.
Destiny's IPO gives it £15.3 million to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.
OrbiMed has launched its third Asia-focused biopharma and healthcare fund with more than half a billion dollars’ worth of private equity.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.